Skip to main navigation
Day One Bio
  • Our Company
    • Mission & Strategy
    • Leadership
    • Partnering
    • Contact
  • Medicines
    • OJEMDA™
  • Our Pipeline
    • Development Overview
    • Tovorafenib
    • Pimasertib
    • Clinical Trials
    • Expanded Access
    • Presentations & Posters
    • Investigator-Sponsored Research
  • Join Our Team
    • Career Opportunities
    • Our Culture
    • Diversity & Inclusion
    • Benefits that Matter
  • Investors & Media
    • Company Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Financials & Filings
      • SEC Filings
      • Annual Reports & Proxy
      • Quarterly Results
    • Corporate Governance
      • Governance Documents
      • Leadership
      • Committee Composition
    • Investor Resources
      • Investor FAQs
      • Investor Email Alerts
      • Request Information
  • Patients, Families & Advocates
    • Patients, Families & Advocates
    • News for the Community
    • Our Patient Advocacy
Select Page
Investors & Media

Press Releases

Investors & Media

Press Releases

Dec 17, 2024
Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Nov 20, 2024
Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
Nov 18, 2024
Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference
Oct 30, 2024
Day One Reports Third Quarter 2024 Financial Results and Corporate Progress
Oct 16, 2024
Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024
Jul 30, 2024
Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
Jul 30, 2024
Day One Announces Oversubscribed $175.0 Million Private Placement
Jul 25, 2024
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
Jun 18, 2024
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
May 30, 2024
Day One Announces Sale of Priority Review Voucher for $108 Million

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 14
Investor Contact

Investor Relations
investors@dayonebio.com

Media Contact

Laura Cooper
Media@dayonebio.com

Helpful Tools
  • Print Page
  • Email Alerts
  • RSS Feed
Footer logo
Our Company
  • Mission & Strategy
  • Leadership
  • Partnering
  • Contact
Medicines
  • OJEMDA™
Our Pipeline
  • Development Overview
  • Tovorafenib
  • Pimasertib
  • Clinical Trials
  • Expanded Access
  • Presentations & Posters
  • Investigator-Sponsored Research
Join Our Team
  • Career Opportunities
  • Our Culture
  • Diversity & Inclusion
  • Benefits that Matter
Investors & Media
  • Company Overview
  • Press Releases
  • Events & Presentations
  • Stock Information
  • Financials & Filings
  • Corporate Governance
  • Investor Resources
  • Patients, Families & Advocates
  • News for the Community
  • Our Patient Advocacy
logo
© 2024 Day One Biopharmaceuticals, Inc.
  • Privacy Policy
  • Terms of Use